Journal of the American Academy of Child & Adolescent Psychiatry
New researchChildhood Factors Affecting Persistence and Desistence of Attention-Deficit/Hyperactivity Disorder Symptoms in Adulthood: Results From the MTA
Section snippets
Study Sample
This study was based on data from the National Institute of Mental Health–Multimodal Treatment Study of Children With ADHD (MTA) cohort. The MTA was a 14-month randomized treatment study of 579 children with ADHD, aged 7 to 10 years, with naturalistic follow-ups to 16 years after baseline. Follow-up assessments were made in childhood (3 years after baseline), adolescence (6, 8, and 10 years after baseline), and adulthood (12, 14, and 16 years after baseline). The current study uses data from
Results
Based on DSM-5 symptom count, 226 (49.9%) of participants were classified as symptom persisters and 227 (50.1%) as symptom desisters. Table 1 presents distributions of baseline variables in the complete-case dataset (Table S3, available online, presents distributions of variables in the imputed dataset).
Logistic regression analyses on the imputed dataset showed that childhood comorbidity was associated with a 15% likelihood of ADHD symptom persistence (odds ratio [OR] = 1.15, standard error
Discussion
This study investigated childhood factors that predict a risk for persistence of ADHD into adulthood. Childhood psychiatric comorbidity, parental mental health, parental marital relationships, and parenting styles were associated with persisting ADHD symptomatology. Of the four above-mentioned predictors, only childhood comorbidity and parental mental health were consistently associated with adult ADHD symptom persistence. We found no associations of IQ, household income, parental education, or
References (44)
- et al.
Attention-deficit/hyperactivity disorder in adults: an overview
Biol Psychiatry
(2000) - et al.
How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD
Psychiatry Res
(2010) - et al.
Adolescent outcomes of childhood attention-deficit/hyperactivity disorder in a diverse community sample
J Am Acad Child Adolesc Psychiatry
(2010) - et al.
Predictors of persistent ADHD: an 11-year follow-up study
J Psychiatr Res
(2011) - et al.
Childhood predictors of adolescent and young adult outcome in ADHD
J Psychiatr Res
(2015) - et al.
ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
3-Year follow-up of the NIMH MTA study
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study
J Am Acad Child Adolesc Psychiatry
(2009) The veridicality of children's reports of parenting: a review of factors contributing to parent–child discrepancies
Clin Psychol Rev
(2010)- et al.
Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative
Biol Psychiatry
(2009)
Diagnostic and statistical manual of mental disorders (DSM-5)
The consequences of attention-deficit/hyperactivity disorder in adults
J Psychiatr Pract
Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type
Am J Psychiatry
The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies
Psychol Med
Aiming for remission in adults with attention-deficit/hyperactivity disorder: the primary care goal
Postgrad Med
Adolescent outcome of child ADHD in primary care setting: stability of diagnosis
J Atten Disord
Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study
J Clin Psychiatry
Psychopathology and symptom remission at adolescence among children with attention-deficit-hyperactivity disorder
Aust N Z J Psychiatry
Predictors of ADHD persistence in girls at 5-year follow-up
J Atten Disord
Analysis of personal and family factors in the persistence of attention deficit hyperactivity disorder: results of a prospective follow-up study in childhood
PLoS One
Persistence of parent-reported ADHD symptoms from childhood through adolescence in a community sample
J Atten Disord
Predictors of persistence in girls with attention deficit hyperactivity disorder: results from an 11-year controlled follow-up study
Acta Psychiatr Scand
Cited by (0)
This article is discussed in an editorial by Dr. James J. McGough on page 925.
Clinical guidance is available at the end of this article.
The work reported was supported by cooperative agreement grants and contracts from the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA) to the following: University of California–Berkeley: U01 MH50461, N01MH12009, and HHSN271200800005-C; DA-8-5550; Duke University: U01 MH50477, N01MH12012, and HHSN271200800009-C; DA-8-5554; University of California– Irvine: U01MH50440, N01MH12011, and HHSN271200800006-C; DA-8-5551; Research Foundation for Mental Hygiene (New York State Psychiatric Institute/Columbia University): U01 MH50467, N01 MH12007, and HHSN271200800007-C; DA-8-5552; Long Island–Jewish Medical Center: U01 MH50453; New York University: N01MH 12004 and HHSN271200800004-C; DA-8-5549; University of Pittsburgh: U01 MH50467, N01 MH 12010, and HHSN271200800008-C; DA-8-5553; DA039881; and McGill University: N01MH12008 and HHSN271200800003-C; DA-8-5548. Dr. Roy was supported by the Ter Meulen grant of the Royal Netherlands Academy of Arts and Sciences (KNAW) to participate in this study. Drs. Roy and Hechtman had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have made substantial contributions to this study and qualify for authorship. Study concept and design: Drs. Roy, Hechtman, Arnold, and Howard. Acquisition, analysis, or interpretation of data: all authors. Manuscript drafting: Drs. Roy and Hechtman. Critical revision of the manuscript for important intellectual content: all authors. Final approval of version to be published: all authors. Obtained funding: Drs. Hechtman, Molina, and Swanson.
The Multimodal Treatment Study of Children with ADHD (MTA) was a National Institute of Mental Health (NIMH) cooperative agreement randomized clinical trial, continued under an NIMH contract as a follow-up study and finally under a National Institute on Drug Abuse (NIDA) contract. Collaborators from NIMH: Benedetto Vitiello, MD (Child and Adolescent Treatment and Preventive Interventions Research Branch), Joanne B. Severe, MS (Clinical Trials Operations and Biostatistics Unit, Division of Services and Intervention Research), Peter S. Jensen, MD (currently at REACH Institute and Mayo Clinic), L. Eugene Arnold, MD, Med (currently at Ohio State University), Kimberly Hoagwood, PhD (currently at Columbia); previous contributors from NIMH to the early phases: John Richters, PhD (currently at National Institute of Nursing Research); Donald Vereen, MD (currently at NIDA). Principal investigators and co-investigators from the sites are: University of California, Berkeley/San Francisco: Stephen P. Hinshaw, PhD (Berkeley), Glen R. Elliott, PhD, MD (San Francisco); Duke University: Karen C. Wells, PhD, Jeffery N. Epstein, PhD (currently at Cincinnati Children's Hospital Medical Center), Desiree W. Murray, PhD; previous Duke contributors to early phases: C. Keith Conners, PhD (former PI); John March, MD, MPH; University of California, Irvine: James Swanson, PhD, Timothy Wigal, PhD; previous contributor from UCLA to the early phases: Dennis P. Cantwell, MD (deceased); New York University School of Medicine: Howard B. Abikoff, PhD; Montreal Children's Hospital/McGill University: Lily Hechtman, MD; New York State Psychiatric Institute/Columbia University/Mount Sinai Medical Center: Laurence L. Greenhill, MD (Columbia), Jeffrey H. Newcorn, MD (Mount Sinai School of Medicine); University of Pittsburgh: Brooke Molina, PhD, Betsy Hoza, PhD (currently at University of Vermont), William E. Pelham, PhD (PI for early phases, currently at Florida International University). Follow-up phase statistical collaborators: Robert D. Gibbons, PhD (University of Illinois, Chicago); Sue Marcus, PhD (Mt. Sinai College of Medicine); Kwan Hur, PhD (University of Illinois, Chicago). Original study statistical and design consultant: Helena C. Kraemer, PhD (Stanford University). Collaborator from the Office of Special Education Programs/US Department of Education: Thomas Hanley, EdD. Collaborator from Office of Juvenile Justice and Delinquency Prevention/Department of Justice: Karen Stern, PhD.
Disclosure: Dr. Hechtman has received research support, served on advisory boards, and served as a speaker for Eli Lilly and Co., GlaxoSmithKline, Ortho-Janssen, Purdue, Shire, and Ironshore. Dr. Arnold has received research funding from Curemark, Forest, Eli Lilly and Co., Neuropharm, Novartis, Noven, Shire, YoungLiving, the National Institutes of Health, Autism Speaks, and Supernus; has consulted with or been on advisory boards for Arbor, Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, Tris Pharma, and Waypoint; and has received travel support from Noven. Drs. Roy, Sibley, Molina, Swanson, and Howard report no biomedical financial interests or potential conflicts of interest.